Format

Send to

Choose Destination
Immunopharmacol Immunotoxicol. 2016;38(1):21-8. doi: 10.3109/08923973.2015.1102934. Epub 2015 Nov 9.

Single-domain antibodies for biomedical applications.

Author information

1
a Protein Engineering and Antibody Technologies , Merck-Serono, Merck KGaA, Darmstadt , Germany .
2
b Institute for Organic Chemistry and Biochemistry, Technische Universität Darmstadt , Darmstadt , Germany , and.
3
c Department Drug Design and Optimization , Helmholtz-Institute for Pharmaceutical Research Saarland (HIPS), Saarland University , Saarbrücken , Germany.

Abstract

Single-domain antibodies are the smallest antigen-binding units of antibodies, consisting either only of one variable domain or one engineered constant domain that solely facilitates target binding. This class of antibody derivatives comprises naturally occurring variable domains derived from camelids and sharks as well as engineered human variable or constant antibody domains of the heavy or light chain. Because of their high affinity and specificity as well as stability, small size and benefit of multiple re-formatting opportunities, those molecules emerged as promising candidates for biomedical applications and some of these entities have already proven to be successful in clinical development.

KEYWORDS:

Antibody engineering; IgNAR; VHH; antibody fragment; heavy chain antibody; single chain binding domain

PMID:
26551147
DOI:
10.3109/08923973.2015.1102934
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center